Polyfunctional response by ImmTAC (IMCgp100) redirected CD8⁺ and CD4⁺ T cells

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer immunotherapies rely on robust immune responses involving diverse effector cells.
• Immune mobilizing monoclonal T cell receptors (ImmTACs) redirect T cells to target tumors.
• IMCgp100 is an ImmTAC designed to target melanoma-specific antigen gp100.

Purpose of the Study:

• To investigate the ability of IMCgp100 to activate and redirect both CD8+ and CD4+ T cell repertoires.
• To assess the cytotoxic potential and cytokine secretion profile of IMCgp100-redirected T cells.
• To demonstrate the induction of broad, polyfunctional anti-cancer immune responses by IMCgp100.

Main Methods:

• Utilized isolated CD8+ and CD4+ T cell subpopulations.
• Assessed T cell killing of melanoma cells upon IMCgp100 redirection.
• Measured secretion of pro-inflammatory cytokines and chemokines by redirected T cells.
• Analyzed the phenotype of IMCgp100-redirected T cells at the single-cell level.

Main Results:

• IMCgp100 efficiently redirected and activated both CD8+ and CD4+ effector and memory T cells.
• Both CD8+ and CD4+ T cells redirected by IMCgp100 exhibited potent melanoma cell killing.
• The majority of T cell subsets secreted key pro-inflammatory cytokines and chemokines.
• IMCgp100-redirected T cells displayed a polyfunctional phenotype, indicative of a strong anti-cancer response.

Conclusions:

• IMCgp100 induces broad immune responses, including CD8+ and CD4+ T cell-mediated cytotoxicity.
• The findings support the clinical development of IMCgp100 for malignant melanoma treatment.
• IMCgp100 demonstrates potential as a single agent or in combination therapies.